Novartis has set out the next steps for its separation from Sandoz, after the parent company’s board unanimously endorsed the long-planned spinoff that will set up the generics and biosimilars giant as an independent standalone company.
Indicating that the separation from Sandoz is expected to be completed “in early Q4 2023,” Novartis said that the next step in the process following the board vote would see shareholders invited to vote on the proposed spin-off – and a related reduction of the share
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?